Technical Analysis for TCRX - TScan Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | -6.52% | |
| Earnings Movers | Other | -6.52% | |
| Wide Bands | Range Expansion | -6.52% | |
| Overbought Stochastic | Strength | -6.52% | |
| New 52 Week Closing High | Bullish | -8.00% | |
| New Uptrend | Bullish | -8.00% | |
| 180 Bullish Setup | Bullish Swing Setup | -8.00% | |
| Slingshot Bullish | Bullish Swing Setup | -8.00% | |
| Upper Bollinger Band Walk | Strength | -8.00% | |
| Wide Bands | Range Expansion | -8.00% |
| Alert | Time |
|---|---|
| Fell Below 10 DMA | about 1 hour ago |
| 10 DMA Support | about 2 hours ago |
| Down 1 ATR | about 2 hours ago |
| Down 5% | about 2 hours ago |
| Down 3% | about 3 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.09 |
| 52 Week Low | 1.94 |
| Average Volume | 206,821 |
| 200-Day Moving Average | 4.96 |
| 50-Day Moving Average | 7.37 |
| 20-Day Moving Average | 7.66 |
| 10-Day Moving Average | 8.07 |
| Average True Range | 0.51 |
| RSI (14) | 66.78 |
| ADX | 26.79 |
| +DI | 30.11 |
| -DI | 11.78 |
| Chandelier Exit (Long, 3 ATRs) | 7.56 |
| Chandelier Exit (Short, 3 ATRs) | 8.11 |
| Upper Bollinger Bands | 8.96 |
| Lower Bollinger Band | 6.36 |
| Percent B (%b) | 0.89 |
| BandWidth | 33.88 |
| MACD Line | 0.38 |
| MACD Signal Line | 0.23 |
| MACD Histogram | 0.1489 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.23 | ||||
| Resistance 3 (R3) | 9.26 | 9.10 | 9.14 | ||
| Resistance 2 (R2) | 9.10 | 8.96 | 9.09 | 9.11 | |
| Resistance 1 (R1) | 8.89 | 8.87 | 8.81 | 8.86 | 9.07 |
| Pivot Point | 8.73 | 8.73 | 8.69 | 8.72 | 8.73 |
| Support 1 (S1) | 8.51 | 8.59 | 8.44 | 8.48 | 8.27 |
| Support 2 (S2) | 8.36 | 8.50 | 8.34 | 8.23 | |
| Support 3 (S3) | 8.14 | 8.36 | 8.20 | ||
| Support 4 (S4) | 8.11 |
